Eiger Biopharmaceuticals - Articles and news items

Results of Phase 2 study of lonafarnib in HDV infected patients published

Industry news / 20 July 2015 / Victoria White

Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+